(1R, 3S)-(-)-Trans-PAT: A novel full-efficacy serotonin 5-HT2C receptor agonist with 5-HT2A and 5-HT2B receptor inverse agonist/antagonist activity

European Journal of Pharmacology

Volumn 615, Issue 1-3, 2009, Pages 1-9

  Booth, Raymond G ^a   Fang, Lijuan ^a   Huang, Yingsu ^a   Wilczynski, Andrzej ^a   Sivendran, Sashikala ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Drug addiction; Drug discovery; Obesity; Psychiatric disorder; Serotonin 5 HT2 receptor

Indexed keywords

1 PHENYL 3 DIMETHYLAMINO 1,2,3,4 TETRAHYDRONAPHTHALENE; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C AGONIST; SEROTONIN 2C RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHEMICAL BOND; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; MENTAL DISEASE; MOLECULAR MODEL; NONHUMAN; OBESITY; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BLOCKING; STEREOCHEMISTRY;

ANIMALS; BINDING SITES; CELL LINE; CHO CELLS; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG INVERSE AGONISM; HUMANS; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2B; SEROTONIN 5-HT2 RECEPTOR AGONISTS; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; STEREOISOMERISM; TETRAHYDRONAPHTHALENES;

EID: 67449138573     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.04.035     Document Type: Article

References (45)

1. Bakker R.A., Dees G., Carrillo J.J., Booth R.G., Lopez-Gimenez J.F., Milligan G., Strange P.G., and Leurs R. Domain swapping in the human histamine H1 receptor. J. Pharmacol. Exp. Ther. 311 (2004) 131-138
2. Ballesteros J.A., Shi L., and Javitch J.A. Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. Mol. Pharmacol. 60 (2001) 1-19
3. Berendsen H.J.C., Postma J.P.M., van Gunsteren W.F., and Hermans J. Interaction models for water in relation to protein hydration. Intermolecular Forces (1981), D. Reidel Publishing Company, Dordrecht, the Netherlands 331-342
4. Berger O., Edholm O., and Jähnig F. Molecular dynamics simulations of a fluid bilayer of dipalmitoylphosphatidylcholine at full hydration, constant pressure, and constant temperature. Biophys. J. 72 (1997) 2002-2013
5. 2C receptors in mouse models of psychosis and obesity Impact of a novel compound. American College of Neuropsychopharmacology Abstracts Annual Meeting, Boca Raton, Florida, December 9-13 (2007)
6. Bubar M.J., and Cunningham K.A. Prospects for serotonin 5-HT2R receptor pharmacology in psychostimulant abuse. Prog. Brain Res. 172 (2008) 319-346
7. Droogmans S., Franken P.R., Garbar C., Weytjens C., Cosyns B., Lahoutte T., Caveliers V., Pipeleers-Marichal M., Bossuyt A., Schoors D., and van Camp G. In vivo model of drug-induced valvular heart disease in rats: pergolide-induced valvular heart disease demonstrated with echocardiography and correlation with pathology. Eur. Heart J. 28 (2007) 2156-2162
8. Fitzgerald L.W., Burn T.C., Brown B.S., Patterson J.P., Corjay M.H., Valentine P.A., Sun J.H., Link J.R., Abbaszade I., Hollis J.M., Largent B.L., Hartig P.R., Hollis G.F., Meunier P.C., Robichaud A.J., and Robertson D.W. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol. Pharmacol. 57 (2000) 75-81
9. Fletcher P.J., Grottick A.J., and Higgins G.A. Differential effects of the 5-HT(2A) receptor antagonist M100907 and the 5-HT(2C) receptor antagonist SB242084 on cocaine-induced locomotor activity, cocaine self-administration and cocaine-induced reinstatement of responding. Neuropsychopharmacology 27 (2002) 576-586
10. Fox S.H., and Brotchie J.M. 5-HT(2C) receptor antagonists enhance the behavioural response to dopamine D(1) receptor agonists in the 6-hydroxydopamine-lesioned rat. Eur. J. Pharmacol. 398 (2000) 59-64
11. Fox S.H., and Brotchie J.M. 5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease. Mov. Disord. 15 (2000) 1064-1069
12. Gehlert D.R., Dreshfield L., Tinsley F., Benvenga M.J., Gleason S., Fuller R.W., Wong D.T., and Hemrick-Luecke S.K. The selective norepinephrine reuptake inhibitor, LY368975, reduces food consumption in animal models of feeding. J. Pharmacol. Exp. Ther. 287 (1998) 122-127
13. Heisler L.K., Zhou L., Bajwa P., Hsu J., and Tecott L.H. Serotonin 5-HT(2C) receptors regulate anxiety-like behavior. Genes Brain Behav. 6 (2007) 491-496
14. Hess B., Bekker H., and Fraaije J.G.E.M. LINCS: a linear constraint solver for molecular simulations. J. Comput. Chem 18 (1997) 1463-1472
15. Jensen M.D. Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors. Obesity 14 (2006) 143S-149S
16. Jorgensen W.L., Maxwell D.S., and Tirado-Rives J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J. Am. Chem. Soc. 118 (1996) 11225-11236
17. Knight A.R., Misra A., Quirk K., Benwell K., Revell D., Kennett G., and Bickerdike M. Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 370 (2004) 114-123
18. Kroeze W.K., Hufeisen S.J., Popadak B.A., Renock S.M., Steinberg S., Ernsberger P., Jayathilake K., Meltzer H.Y., and Roth B.L. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28 (2003) 519-526
19. Launay J.M., Herve P., Peoc'h K., Tournois C., Callebert J., Nebigil C.G., Etienne N., Drouet L., Humbert M., Simonneau G., and Maroteaux L. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat. Med. 8 (2002) 1129-1135
20. Lindahl E., Hess B., and van der Spoel D. GROMACS 3.0: a package for molecular simulation and trajectory analysis. J. Mol. Model 7 (2001) 306-317
21. Moniri N.H., and Booth R.G. Role of PKA and PKC in histamine H1 receptor-mediated activation of catecholamine neurotransmitter synthesis. Neurosci. Lett. 407 (2006) 249-253
22. Moniri N.H., Covington-Strachan D., and Booth R.G. Ligand-directed functional heterogeneity of histamine H1 receptors: novel dual-function ligands selectively activate and block H1-mediated phospholipase C and adenylyl cyclase signaling. J. Pharmacol. Exp. Ther. 311 (2004) 274-281
23. Muntasir H.A., Takahashi J., Rashid M., Ahmed M., Komiyama T., Hossain M., Kawakami J., Nashimoto M., and Nagatomo T. Site-directed mutagenesis of the serotonin 5-Hydroxytryptamine2c receptor: identification of amino acids responsible for sarpogrelate binding. Biol. Pharm. Bull. 29 (2006) 1645-1650
24. Muntasir H.A., Rashid M., Komiyama T., Kawakami J., and Nagatomo T. Identification of amino acid residues important for sarpogrelate binding to the human 5-hydroxytryptamine2A serotonin receptor. J. Pharmacol. Sci 102 (2006) 55-63
25. Muntasir H.A., Hossain M., Bhuiyan M.A., Komiyama T., Nakamura T., Ozaki M., and Nagatomo T. Identification of a key amino acid of the human 5-HT(2B) serotonin receptor important for sarpogrelate binding. J. Pharmacol. Sci 104 (2007) 274-277
26. Nichols D.E. Hallucinogens. Pharmacol. Ther. 101 (2004) 131-181
27. Okada T., Fujiyoshi Y., Silow M., Navarro J., Landau E.M., and Shichida Y. Functional role of internal water molecules in rhodopsin revealed by X-ray crystallography. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 5982-5987
28. PDSP (2005) Psychoactive Drug Screening Program, BL Roth, Director. NIMH Contract NO2MH80002, University of North Carolina, Chapel Hill, NC; Novascreen (1996) NIMH Psychotherapeutic Drug Discovery and Development Program, Oceanix Biosciences Corporation.
29. Porter R.H., Benwell K.R., Lamb H., Malcolm C.S., Allen N.H., Revell D.F., Adams D.R., and Sheardown M.J. Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells. Br. J. Pharmacol. 128 (1999) 13-20
30. Raymond J.R., Mukhin Y.V., Gelasco A., Turner J., Collinsworth G., Gettys T.W., Grewal J.S., and Garnovskaya M.N. Multiplicity of mechanisms of serotonin receptor signal transduction. Pharmacol. Ther. 92 (2001) 179-212
31. Rosenzweig-Lipson S., Zhang J., Mazandarani H., Harrison B.L., Sabb A., Sabalski J., Stack G., Welmaker G., Barrett J.E., and Dunlop J. Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161503. Brain Res. 1073-1074 (2006) 240-251
32. Rosenzweig-Lipson S., Sabb A., Stack G., Mitchell P., Lucki I., Malberg J.E., Grauer S., Brennan J., Cryan J.F., Sukoff Rizzo S.J., Dunlop J., Barrett J.E., and Marquis K.L. Antidepressant-like effects of the novel, selective, 5-HT(2C) receptor agonist WAY-163909 in rodents. Psychopharmacology (Berl.) 192 (2007) 159-170
33. Rothman R.B., Ayestas M.A., Dersch C.M., and Baumann M.H. Aminorex, fenfluramine and chlorphentermine are serotonin transporter substrates: implications for primary pulmonary hypertension. Circulation 100 (1999) 869-875
34. Rowland N.E., Crump E.M., Nguyen N., Robertson K., Sun Z., and Booth R.G. Effect of (-)-trans-PAT, a novel 5-HT2C receptor agonist, on intake of palatable food in mice. Pharmacol. Biochem. Behav. 91 (2008) 176-180
35. 1C receptor subtypes. Biochem. Biophys. Res. Commun. 181 (1991) 1469-7148
36. 2B receptor. Mol. Pharmacol. 68 (2005) 20-33
37. Simansky K.J. NIH symposium series: ingestive mechanisms in obesity, substance abuse and mental disorders. Physiol. Behav. 86 (2005) 1-4
38. Siuciak J.A., Chapin D.S., McCarthy S.A., Guanowsky V., Brown J., Chiang P., Marala R., Patterson T., Seymour P.A., Swick A., and Iredale P.A. CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity. Neuropharmacology 52 (2007) 279-290
39. Smith S.R., Prosser W., Donahue D., Anderson C., and Shanahan W. Lorcaserin Phase 2b Clinical Study (2006), American Diabetes Association
40. Tecott L.H., Sun L.M., Akana S.F., Strack A.M., Lowenstein D.H., Dallman M.F., and Julius D. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 374 (1995) 542-546
41. Thomsen W.J., Grottick A.J., Menzaghi F., Reyes-Saldana H., Espitia S., Yuskin D., Whelan K., Martin M., Morgan M., Chen W., Al-Shamma H., Smith B., Chalmers D., and Behan D. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J. Pharmacol. Exp. Ther. 325 (2008) 577-587
42. Vickers S.P., Dourish C.T., and Kennett G.A. Evidence that hypophagia induced by D-fenfluramine and D-norfenfluramine in the rat is mediated by 5-HT2C receptors. Neuropharmacology 41 (2001) 200-209
43. Wellman P.J., and Davies B.T. Reversal of phenylpropanolamine anoxexia in rats by the alpha-1 receptor antagonist benoxathian. Pharmacol. Biochem. Behav. 38 (1991) 905-908
44. Wyrick S.D., Booth R.G., Myers A.M., Owens C.E., Kula N.S., Baldessarini R.J., and Mailman R.B. Synthesis and pharmacological evaluation of 1-phenyl-3-amino-1,2,3,4-tetrahydronaphthalenes as ligands for a novel receptor with sigma-like neuromodulatory activity. J. Med. Chem. 36 (1993) 2542-2551
45. York D.M., Darden T.A., Pedersen L.G., and Anderson M.W. Molecular dynamics simulation of HIV-1 protease in a crystalline environment and in solution. Biochemistry 32 (1993) 1443-1453